The U.S. Food and Drug Administration (FDA) has just approved a drug for treating binge eating disorder. Known by the name of Vyvanse, this will be the first product of its kind in the market to be approved for treating this particular disorder. Though it has already been approved for use on patients with attention deficit disorder, its use has now been expanded to include those who tend to binge eat.
Some people tend to overeat due to mental or emotional problems. They seem to be unable to control their eating and can eat to the point of being uncomfortably full for three straight days a week. Though the exact cause associated with the disorder has not yet been pinpointed, health experts believe it is linked to both biological and psychological factors.
Whatever the reason causing it, there can be no denying that eating uncontrollably can cause serious health problems including putting the people affected by the disorder to greater risk of being overweight or obese. With some of the chronic diseases in the world today like Type II diabetes, hypertension and certain cancers being linked o obesity, it becomes very important to control the urge to eat beyond what is required by the body.
The American Psychiatric Association recognizes binge eating disorder as a mental disorder, meaning thereby that they believe it can be treated with a prescription.
The U.S. Food and Drug Administration explains: “In binge-eating disorder, patients have recurrent episodes of compulsive overeating during which they consume larger amounts of food than normal and experience the sense that they lack control. Patients with this condition eat when they are not hungry and often eat to the point of being uncomfortably full.”
Furthermore, the agency describes, “Patients may feel ashamed and embarrassed by how much they are eating, which can result in social isolation. Binge-eating disorder may lead to weight gain and to health problems related to obesity.
As the clinical studies have shown that Vyvanse can help cut down on the number of binges attempted by a patient in a week, the FDA has approved the drug. The process of approval has gone through a priority review, meaning it got a quick approval due to an expedited process.